Survival Duration in Diastolic Heart Failure (HFpEF)
Patients with diastolic heart failure (HFpEF) have a median survival of approximately 2-3 years after hospitalization, with 5-year mortality rates reaching 47-75%, comparable to heart failure with reduced ejection fraction.
Mortality Rates Over Time
The prognosis for HFpEF is sobering and often underestimated. Based on the highest quality recent evidence:
- 1-year mortality: 15% 1
- 3-year mortality: 31% 1
- 5-year mortality: 47-75% 1, 2, 3
- 10-year mortality: 74% 1
The median survival across all HFpEF patients is approximately 2.1 years after hospitalization 3. This is markedly lower than age-matched individuals in the general U.S. population across all age groups 3.
Annual Event Rates
Beyond mortality, the disease burden is substantial:
- Annual mortality rate: Approximately 15% per year 4
- Hospitalizations: Patients average 1.4 hospitalizations per year 4
- Combined mortality or HF hospitalization: 84% at 10 years, with an incidence rate of 227 per 1,000 patient-years 1
Critical Prognostic Factors
The following factors independently predict worse survival:
- Tricuspid regurgitation peak velocity (strongest cardiac predictor) 1
- Diabetes mellitus 1
- Cancer diagnosis 1
- Male sex (women have better survival) 1
- Higher diagnostic scores (HFA-PEFF score ≥6 or H2FPEF probability >95%) correlate with median survival of only 28 months versus 65 months for lower scores 5
Comparison Across Heart Failure Types
Importantly, outcomes in HFpEF are comparable to—not better than—heart failure with reduced ejection fraction. Risk-adjusted 5-year mortality is essentially identical across all ejection fraction categories (approximately 75-76%) 3. This contradicts the historical misconception that "preserved" ejection fraction implies preserved prognosis 6, 7.
Clinical Implications
The guideline evidence emphasizes that HFpEF now accounts for more than 50% of all heart failure cases, with outcomes comparable to HFrEF 6. Despite recent therapeutic advances with SGLT2 inhibitors (dapagliflozin, empagliflozin) reducing HF hospitalization or cardiovascular death by approximately 20% 4, the overall prognosis remains poor.
Common pitfall: Clinicians often underestimate the severity of HFpEF because the ejection fraction is "preserved." The evidence clearly shows this is a lethal condition requiring aggressive management of both cardiac dysfunction and comorbidities 6, 1.
The trajectory is particularly concerning in patients with elevated filling pressures on stress testing, multiple comorbidities (especially diabetes and atrial fibrillation), and evidence of right ventricular dysfunction (elevated tricuspid regurgitation velocity) 1, 5.